The Residual Vaccine-preventable Burden of Rotavirus Disease

Bethany K Sederdahl; Jumi Yi; Robert Jerris; Scott E Gillespie; Lars Westblade; Colleen S Kraft; Andi L Shane; Ben Lopman; Evan J Anderson

doi:10.1097/INF.0000000000001580

The Residual Vaccine-preventable Burden of Rotavirus Disease

Pediatr Infect Dis J. 2017 Aug;36(8):780-781. doi: 10.1097/INF.0000000000001580.

Authors

Bethany K Sederdahl¹, Jumi Yi, Robert Jerris, Scott E Gillespie, Lars Westblade, Colleen S Kraft, Andi L Shane, Ben Lopman, Evan J Anderson

Affiliation

¹ From the *Department of Pediatrics, Emory University School of Medicine, †Rollins School of Public Health, Emory University, ‡Children's Healthcare of Atlanta, §Department of Pathology and Laboratory Medicine, Emory University School of Medicine, and ¶Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.

PMID: 28221240
DOI: 10.1097/INF.0000000000001580

Abstract

From July 2007 to June 2015, 61% of rotavirus-positive, vaccine-eligible children were unvaccinated for rotavirus. Of these, 67% of children had received diphtheria-tetanus toxoids-acellular pertussis within the recommended age for rotavirus vaccine initiation. Improving linkage between rotavirus and diphtheria-tetanus toxoids-acellular pertussis administration may impact the residual burden of US rotavirus disease.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Humans
Immunization / statistics & numerical data*
Immunization Schedule*
Infant
Retrospective Studies
Rotavirus Infections / epidemiology*
Rotavirus Infections / prevention & control*
Rotavirus Vaccines / administration & dosage*
Rotavirus Vaccines / therapeutic use

Substances

Rotavirus Vaccines